{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:34:26Z","timestamp":1770474866631,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,23]],"date-time":"2002-01-23T00:00:00Z","timestamp":1011744000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p>Objective.\u2014Evaluate the long\u2010term tolerability of almotriptan 12.5 mg for the treatment of acute migraine attacks occurring over a 6\u2010month period.<\/jats:p>\n                  <jats:p>\n                    Background.\u2014Almotriptan is a second\u2010generation 5\u2010HT\n                    <jats:sub>1B\/1D<\/jats:sub>\n                    agonist that exhibits vascular selectivity for meningeal arteries and has demonstrated efficacy for the treatment of acute migraine in short\u2010term controlled trials.\n                  <\/jats:p>\n                  <jats:p>Methods.\u2014This was a 6\u2010month open\u2010label study. Adults (18 years of age or older) were required to have a diagnosis of acute migraine with or without aura (according to the diagnostic criteria of the International Headache Society), a history of at least 1 year of moderate\u2010to\u2010severe migraine pain with at least two and a maximum of six migraines per month, and at least 24 hours of freedom from head pain between attacks. Patients were instructed to take a single 12.5\u2010mg dose of almotriptan at the onset of a migraine attack. If migraine pain did not disappear in 2 hours, escape medication could be taken; if relapse occurred in less than 24 hours, a second 12.5\u2010mg dose could be taken. Tolerability was assessed from the nature and incidence of all adverse events, and efficacy was assessed according to the end point of pain relief 2 hours following almotriptan administration.<\/jats:p>\n                  <jats:p>Results.\u2014Of 585 patients treated, 582 were included in the intent\u2010to\u2010treat population. The most frequent drug\u2010related adverse events were nausea (3.1%) and dizziness (2.4%). No serious drug\u2010related adverse events were reported, and no deaths occurred. Adverse events led to discontinuation of treatment in 36 patients (6.2%). Drug\u2010related chest pain was reported in 9 patients (1.5%). Seventy\u2010six percent of patients achieved pain relief at 2 hours for all attacks treated, and 49% were pain\u2010free at 2 hours. After a second dose of almotriptan 12.5 mg, pain relief was achieved in 87% of attacks, and 59% were pain\u2010free. Pain relief and pain\u2010free rates were higher among those with moderate baseline pain.<\/jats:p>\n                  <jats:p>Conclusions.\u2014When taken at attack onset, almotriptan 12.5 mg is well tolerated, safe, and effective for the long\u2010term treatment of acute migraine.<\/jats:p>","DOI":"10.1046\/j.1526-4610.2002.02011.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T06:49:38Z","timestamp":1027666178000},"page":"32-40","source":"Crossref","is-referenced-by-count":3,"title":["A Long\u2010term Open\u2010Label Study of Oral Almotriptan 12.5 mg for the Treatment of Acute Migraine"],"prefix":"10.1111","volume":"42","author":[{"given":"Ninan T.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"For The Oral Almotriptan Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,23]]},"reference":[{"issue":"7","key":"e_1_2_7_2_2","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.","volume":"8","author":"Headache Classification Committee of the International Headache Society","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70291-7"},{"issue":"4","key":"e_1_2_7_4_2","first-page":"S17","article-title":"Migraine prevalence. A review of population\u2010based studies.","volume":"44","author":"Stewart WF","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11370-8"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480010072027"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100000147"},{"key":"e_1_2_7_8_2","first-page":"18","article-title":"Serotonin receptors and the acute attack of migraine.","volume":"5","author":"Goadsby PJ","year":"1998","journal-title":"Clin Neurosci"},{"key":"e_1_2_7_9_2","first-page":"593","article-title":"Physiopathology of the migraine attack and mechanisms of action of anti\u2010migraine agents: recent findings in animals [in French].","volume":"48","author":"Mick G","year":"2000","journal-title":"Pathol Biol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060060-00003"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-199906000-00004"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009431"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1996.1604264.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191159"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1996.1608554.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00876-1"},{"key":"e_1_2_7_17_2","first-page":"421","article-title":"Efficacy data on oral almotriptan, a novel 5HT1D agonist [abstract].","volume":"17","author":"Cabarrocas X","year":"1997","journal-title":"Cephalalgia"},{"key":"e_1_2_7_18_2","first-page":"362","article-title":"Oral almotriptan in the treatment of migraine. A dose finding study [abstract].","volume":"19","author":"Fernandez FJ","year":"1999","journal-title":"Cephalalgia"},{"key":"e_1_2_7_19_2","first-page":"377","article-title":"Equivalent efficacy of oral almotriptan, a new 5\u2010HT1B\/1D agonist, compared with sumatriptan 100 mg [abstract].","volume":"38","author":"Cabarrocas X","year":"1998","journal-title":"Headache"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00091.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1991.1101001.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006057.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958020-00016"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958040-00013"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1996.3605329.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200103000-00006"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-4610.2002.02011.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-4610.2002.02011.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:05:52Z","timestamp":1762088752000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-4610.2002.02011.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1046\/j.1526-4610.2002.02011.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-4610.2002.02011.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}